palmidrol has been researched along with Migraine Disorders in 4 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "All patients had a diagnosis of migraine without aura (ICHD 3 criteria) and received umPEA (600 mg/day orally) for three months." | 2.94 | Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study. ( Alaimo di Loro, P; Ferilli, MAN; Moavero, R; Papetti, L; Sforza, G; Tarantino, S; Tullo, G; Ursitti, F; Valeriani, M; Vigevano, F, 2020) |
| "PEA nutraceuticals could be useful in migraine prevention." | 1.72 | Palmitoylethanolamide-based nutraceutical Calmux® in preventive treatment of migraine. ( Hernández, AG, 2022) |
| "Twenty-four subjects with episodic migraine (MIG) and 19 healthy controls (HC) underwent blood sampling and investigation of nociceptive withdrawal reflex thresholds (RTh: single-stimulus threshold; TST: temporal summation threshold) before and 30 (T30), 60 (T60), and 120 (T120) minutes after sublingual NTG administration (0." | 1.62 | Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks. ( Allena, M; De Icco, R; Demartini, C; Greco, R; Grillo, V; Realini, N; Reggiani, A; Sances, G; Tassorelli, C; Tumelero, E; Vergobbi, P; Zanaboni, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández, AG | 1 |
| Papetti, L | 1 |
| Sforza, G | 1 |
| Tullo, G | 1 |
| Alaimo di Loro, P | 1 |
| Moavero, R | 1 |
| Ursitti, F | 1 |
| Ferilli, MAN | 1 |
| Tarantino, S | 1 |
| Vigevano, F | 1 |
| Valeriani, M | 1 |
| De Icco, R | 1 |
| Greco, R | 1 |
| Demartini, C | 1 |
| Vergobbi, P | 1 |
| Zanaboni, A | 1 |
| Tumelero, E | 1 |
| Reggiani, A | 1 |
| Realini, N | 1 |
| Sances, G | 1 |
| Grillo, V | 1 |
| Allena, M | 1 |
| Tassorelli, C | 1 |
| Sarchielli, P | 1 |
| Pini, LA | 1 |
| Coppola, F | 1 |
| Rossi, C | 1 |
| Baldi, A | 1 |
| Mancini, ML | 1 |
| Calabresi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Factors Associated With Migraine Refractoriness to Preventive Treatments: Psychological Aspects and Relationship With Components of the Endocannabinoid System[NCT05046119] | 80 participants (Anticipated) | Observational | 2021-09-15 | Not yet recruiting | |||
| Habituation of the Nociceptive Blink Reflex in Experimentally Induced Migraine Attack: a Cross-over, Randomized Controlled Study[NCT05718310] | 22 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Peripheral Gene Expression of Endocannabinoid System Components in Episodic and Chronic Migraine Patients: a Pilot Study[NCT04324710] | 75 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for palmidrol and Migraine Disorders
| Article | Year |
|---|---|
Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study.
Topics: Amides; Analgesics; Child; Ethanolamines; Female; Humans; Male; Migraine Disorders; Palmitic Acids; | 2020 |
3 other studies available for palmidrol and Migraine Disorders
| Article | Year |
|---|---|
Palmitoylethanolamide-based nutraceutical Calmux® in preventive treatment of migraine.
Topics: Adult; Amides; Dietary Supplements; Double-Blind Method; Ethanolamines; Female; Humans; Male; Middle | 2022 |
Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks.
Topics: Amides; Ethanolamines; Humans; Migraine Disorders; Nitroglycerin; Nociception; Palmitic Acids | 2021 |
Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks.
Topics: Amides; Ethanolamines; Humans; Migraine Disorders; Nitroglycerin; Nociception; Palmitic Acids | 2021 |
Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks.
Topics: Amides; Ethanolamines; Humans; Migraine Disorders; Nitroglycerin; Nociception; Palmitic Acids | 2021 |
Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks.
Topics: Amides; Ethanolamines; Humans; Migraine Disorders; Nitroglycerin; Nociception; Palmitic Acids | 2021 |
Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Topics: Adult; Amides; Arachidonic Acids; Calcitonin Gene-Related Peptide; Cannabinoid Receptor Modulators; | 2007 |
Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Topics: Adult; Amides; Arachidonic Acids; Calcitonin Gene-Related Peptide; Cannabinoid Receptor Modulators; | 2007 |
Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Topics: Adult; Amides; Arachidonic Acids; Calcitonin Gene-Related Peptide; Cannabinoid Receptor Modulators; | 2007 |
Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Topics: Adult; Amides; Arachidonic Acids; Calcitonin Gene-Related Peptide; Cannabinoid Receptor Modulators; | 2007 |